SRSF2 and acute myeloid leukemia: Interestingly a recent study further highlights that mutational landscapes in CHIP carriers associate with increased propensity to develop specific myeloid malignancies, in detail, SF3B1 and SRSF2/TET2 co‐mutated cases associate with higher risk of MDS, and SRSF2/IDH2 co‐mutated cases are more likely to develop AML.